nach oben

Erschienen in:

20.07.2020 | Preclinical study

Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer

verfasst von: Svetlana Bortnik, Basile Tessier-Cloutier, Samuel Leung, Jing Xu, Karama Asleh, Samantha Burugu, Jamie Magrill, Kendall Greening, Fatemeh Derakhshan, Stephen Yip, Tony Ng, Karen A. Gelmon, Torsten O. Nielsen, Sharon M. Gorski

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Previous studies indicate that breast cancer molecular subtypes differ with respect to their dependency on autophagy, but our knowledge of the differential expression and prognostic significance of autophagy-related biomarkers in breast cancer is limited.

Methods

Immunohistochemistry (IHC) was performed on tissue microarrays from a large population of 3992 breast cancer patients divided into training and validation cohorts. Consensus staining scores were used to evaluate the expression levels of autophagy proteins LC3B, ATG4B, and GABARAP and determine the associations with clinicopathological variables and molecular biomarkers. Survival analyses were performed using the Kaplan–Meier function and Cox proportional hazards regression models.

Results

We found subtype-specific expression differences for ATG4B, with its expression lowest in basal-like breast cancer and highest in Luminal A, but there were no significant associations with patient prognosis. LC3B and GABARAP levels were highest in basal-like breast cancers, and high levels were associated with worse outcomes across all subtypes (DSS; GABARAP: HR 1.43, LC3B puncta: HR 1.43). High ATG4B levels were associated with ER, PR, and BCL2 positivity, while high LC3B and GABARAP levels were associated with ER, PR, and BCL2 negativity, as well as EGFR, HER2, HER3, CA-IX, PD-L1 positivity, and high Ki67 index (p < 0.05 for all associations). Exploratory multi-marker analysis indicated that the combination of ATG4B and GABARAP with LC3B could be useful for further stratifying patient outcomes.

Conclusions

ATG4B levels varied across breast cancer subtypes but did not show prognostic significance. High LC3B expression and high GABARAP expression were both associated with poor prognosis and with clinicopathological characteristics of aggressive disease phenotypes in all breast cancer subtypes.

Nur mit Berechtigung zugänglich

Galluzzi L, Pietrocola F, Bravo-San Pedro JM et al (2015) Autophagy in malignant transformation and cancer progression. EMBO J 34:856–880PubMedPubMedCentral

Amaravadi R, Kimmelman AC, White E (2016) Recent insights into the function of autophagy in cancer. Genes Dev 30:1913–1930PubMedPubMedCentral

Levy JMM, Towers CG, Thorburn A (2017) Targeting autophagy in cancer. Nat Rev Cancer 17:528–542PubMed

Dolgin E (2019) Anticancer autophagy inhibitors attract “resurgent” interest. Nat Rev Drug Discov 18:408–410PubMed

Ravikumar B, Sarkar S, Davies JE et al (2010) Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 90:1383–1435PubMed

Yang Z, Klionsky DJ (2010) Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 22:124–131PubMed

Itakura E, Mizushima N (2010) Characterization of autophagosome formation site by a hierarchical analysis of mammalian Atg proteins. Autophagy 6:764–776PubMedPubMedCentral

Feng Y, He D, Yao Z et al (2014) The machinery of macroautophagy. Cell Res 24:24–41PubMed

Mizushima N, Yoshimori T, Ohsumi Y (2011) The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol 27:107–132PubMed

10.

Nguyen TN, Padman BS, Usher J et al (2016) Atg8 family LC3/GABARAP proteins are crucial for autophagosome–lysosome fusion but not autophagosome formation during PINK1/Parkin mitophagy and starvation. J Cell Biol 251:857

11.

Weidberg H, Shvets E, Shpilka T et al (2010) LC3 and GATE-16/GABARAP subfamilies are both essential yet act differently in autophagosome biogenesis. EMBO J 29:1792–1802PubMedPubMedCentral

12.

Shpilka T, Weidberg H, Pietrokovski S et al (2011) Atg8: an autophagy-related ubiquitin-like protein family. Genome Biol 12:226PubMedPubMedCentral

13.

Schaaf MBE, Keulers TG, Vooijs MA et al (2016) LC3/GABARAP family proteins: autophagy-(un)related functions. FASEB J 30:3961–3978PubMed

14.

Tanida I, Sou Y, Ezaki J et al (2004) HsAtg4B/HsApg4B/autophagin-1 cleaves the carboxyl termini of three human Atg8 homologues and delipidates microtubule-associated protein light chain 3- and GABAA receptor-associated protein-phospholipid conjugates. J Biol Chem 279:36268–36276PubMed

15.

Satoo K, Noda NN, Kumeta H et al (2009) The structure of Atg4B–LC3 complex reveals the mechanism of LC3 processing and delipidation during autophagy. EMBO J 28:1341–1350PubMedPubMedCentral

16.

Fujita N, Hayashi-Nishino M, Fukumoto H et al (2008) An Atg4B mutant hampers the lipidation of LC3 paralogues and causes defects in autophagosome closure. Mol Biol Cell 19:4651–4659PubMedPubMedCentral

17.

Li M, Hou Y, Wang J et al (2011) Kinetics comparisons of mammalian Atg4 homologues indicate selective preferences toward diverse Atg8 substrates. J Biol Chem 286:7327–7338PubMed

18.

Kauffman KJ, Yu S, Jin J et al (2018) Delipidation of mammalian Atg8-family proteins by each of the four ATG4 proteases. Autophagy 14:992–1010PubMedPubMedCentral

19.

Akin D, Wang SK, Habibzadegah-Tari P et al (2014) A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors. Autophagy 10:2021–2035PubMedPubMedCentral

20.

Kurdi A, Cleenewerck M, Vangestel C et al (2017) ATG4B inhibitors with a benzotropolone core structure block autophagy and augment efficiency of chemotherapy in mice. Biochem Pharmacol 138:150–162PubMed

21.

Rothe K, Lin H, Lin KBL et al (2014) The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells. Blood 123:3622–3634PubMed

22.

Tran E, Chow A, Goda T et al (2013) Context-dependent role of ATG4B as target for autophagy inhibition in prostate cancer therapy. Biochem Biophys Res Commun 441:726–731PubMed

23.

Bosc D, Vezenkov L, Bortnik S et al (2018) A new quinoline-based chemical probe inhibits the autophagy-related cysteine protease ATG4B. Sci Rep 8:11653PubMedPubMedCentral

24.

Fu Y, Hong L, Xu J et al (2018) Discovery of a small molecule targeting autophagy via ATG4B inhibition and cell death of colorectal cancer cells in vitro and in vivo. Autophagy 15:1–17

25.

Liu P-F, Tsai K-L, Hsu C-J et al (2018) Drug repurposing screening identifies tioconazole as an ATG4 inhibitor that suppresses autophagy and sensitizes cancer cells to chemotherapy. Theranostics 8:830–845PubMedPubMedCentral

26.

Bortnik S, Choutka C, Horlings HM et al (2016) Identification of breast cancer cell subtypes sensitive to ATG4B inhibition. Oncotarget 7:66970–66988PubMedPubMedCentral

27.

Liu P-F, Leung C-M, Chang Y-H et al (2014) ATG4B promotes colorectal cancer growth independent of autophagic flux. Autophagy 10:1454–1465PubMedPubMedCentral

28.

Liu P-F, Hsu C-J, Tsai W-L et al (2017) Ablation of ATG4B suppressed autophagy and activated AMPK for cell cycle arrest in cancer cells. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 44:728–740

29.

Bortnik S, Gorski SM (2017) Clinical applications of autophagy proteins in cancer: from potential targets to biomarkers. Int J Mol Sci 18:1496PubMedCentral

30.

Lazova R, Camp RL, Klump V et al (2012) Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res Off J Am Assoc Cancer Res 18:370–379

31.

Ladoire S, Chaba K, Martins I et al (2012) Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy 8:1175–1184PubMedPubMedCentral

32.

Lefort S, Joffre C, Kieffer Y et al (2014) Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. Autophagy 10:2122–2142PubMed

33.

Ladoire S, Penault-Llorca F, Senovilla L et al (2015) Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy 11:1878–1890PubMedPubMedCentral

34.

Holt SV, Wyspianska B, Randall KJ et al (2011) The development of an immunohistochemical method to detect the autophagy-associated protein LC3-II in human tumor xenografts. Toxicol Pathol 39:516–523PubMed

35.

Martinet W, Schrijvers DM, Timmermans J-P et al (2013) Immunohistochemical analysis of macroautophagy. Autophagy 9:386–402PubMedPubMedCentral

36.

Bertucci F, Finetti P, Cervera N et al (2008) How basal are triple-negative breast cancers? Int J Cancer 123:236–240PubMed

37.

Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl 1):61–70PubMed

38.

Maycotte P, Gearheart CM, Barnard R et al (2014) STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res 74:2579–2590PubMedPubMedCentral

39.

Maycotte P, Thorburn A (2014) Targeting autophagy in breast cancer. World J Clin Oncol 5:224–240PubMedPubMedCentral

40.

Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100:237–238PubMed

41.

Zhao H, Yang M, Zhao J et al (2013) High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer. Med Oncol Northwood Lond Engl 30:475

42.

Chen S, Jiang Y-Z, Huang L et al (2013) The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Clin Cancer Res Off J Am Assoc Cancer Res 19:6853–6862

43.

Klionsky DJ, Abdelmohsen K, Abe A et al (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1–222PubMedPubMedCentral

44.

Chittaranjan S, Bortnik S, Gorski SM (2015) Monitoring autophagic flux by using lysosomal inhibitors and western blotting of endogenous MAP1LC3B. Cold Spring Harb Protoc 2015:743–750PubMed

45.

He H, Yang Y, Xiang Z et al (2016) A sensitive IHC method for monitoring autophagy-specific markers in human tumor xenografts. J Biomark. https://doi.org/10.1155/2016/1274603CrossRefPubMedPubMedCentral

46.

Yu Z-Q, Ni T, Hong B et al (2012) Dual roles of Atg8−PE deconjugation by Atg4 in autophagy. Autophagy 8:883–892PubMedPubMedCentral

47.

Yang Z, Wilkie-Grantham RP, Yanagi T et al (2015) ATG4B (autophagin-1) phosphorylation modulates autophagy. J Biol Chem 290:26549–26561PubMedPubMedCentral

48.

Huang T, Kim CK, Alvarez AA et al (2017) MST4 phosphorylation of ATG4B regulates autophagic activity, tumorigenicity, and radioresistance in glioblastoma. Cancer Cell 32(840–855):e8

49.

Liu P-F, Chen H-C, Cheng J-S et al (2019) Association of ATG4B and phosphorylated ATG4B proteins with tumorigenesis and prognosis in oral squamous cell carcinoma. Cancers 11:1854PubMedCentral

50.

Cheang MCU, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res Off J Am Assoc Cancer Res 14:1368–1376

51.

Cheang MCU, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750PubMedPubMedCentral

52.

Liu S, Chia SK, Mehl E et al (2010) Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 119:53–61PubMed

53.

Cheang MCU, Treaba DO, Speers CH et al (2006) Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol Off J Am Soc Clin Oncol 24:5637–5644

54.

Jensen KC, Turbin DA, Leung S et al (2008) New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat 112:453–459PubMed

55.

Dawson S-J, Makretsov N, Blows FM et al (2010) BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 103:668–675PubMedPubMedCentral

56.

Lou Y, McDonald PC, Oloumi A et al (2011) Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 71:3364–3376PubMed

57.

Chiu CG, Masoudi H, Leung S et al (2010) HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg 251:1107–1116PubMed

58.

Yerushalmi R, Gelmon KA, Leung S et al (2012) Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 132:131–142PubMed

59.

Chang S-J, Ou-Yang F, Tu H-P et al (2016) Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24−/low) indicate poor prognosis in triple-negative breast cancer. Hum Pathol 48:48–55PubMed

60.

Goossens N, Nakagawa S, Sun X et al (2015) Cancer biomarker discovery and validation. Transl Cancer Res 4:256–269PubMed

61.

Voduc D, Cheang M, Nielsen T (2008) GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res 17:365–373

62.

Burugu S, Gao D, Leung S et al (2017) LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors. Ann Oncol Off J Eur Soc Med Oncol 28:2977–2984

63.

Chia S, Norris B, Speers C et al (2008) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol Off J Am Soc Clin Oncol 26:5697–5704

64.

McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med 22:276–282

Titel: Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer
verfasst von: Svetlana Bortnik
Basile Tessier-Cloutier
Samuel Leung
Jing Xu
Karama Asleh
Samantha Burugu
Jamie Magrill
Kendall Greening
Fatemeh Derakhshan
Stephen Yip
Tony Ng
Karen A. Gelmon
Torsten O. Nielsen
Sharon M. Gorski
Publikationsdatum: 20.07.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05795-z

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry

Diagnostic workup of early-stage breast cancer: can we choose more wisely?

Optimism and coping: do they influence health outcomes in women with breast cancer? A systemic review and meta-analysis

Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies

Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer

Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie